Renal Anemia | Access and Reimbursement | US | 2016
Renal Anemia | Access & Reimbursement | US examines the market access factors that influence the success of therapies for the treatment of renal anemia. The series is based on primary research data with U.S. nephrologists and MCO pharmacy and medical directors. This research explores how payers and physicians interact and how reimbursement decisions impact the prescribing and uptake of specific therapies at the brand level.
Related Market Assessment Reports
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
